66.67% Capital Reduction via 3:1 Stock Consolidation to Cover Deficits
NGeneBio proposes a capital reduction via 3:1 stock consolidation (66.67% reduction) at the extraordinary shareholders' meeting on June 9, 2026, to cover accumulated deficits
Record date for consolidation is June 24, 2026; outstanding shares decrease from 26,809,750 to 8,936,583, and capital stock from 26.8B won to 8.9B won
Fractional shares will be paid in cash based on the closing price on the first listing day; creditor objection procedures are omitted as per law
Trading suspension from June 23 to July 12, 2026; new listing expected on July 13, 2026